AstraZeneca reaches the last stage of testing

The American agency Bloomberg revealed that the US vaccine produced by AstraZeneca has reached its final stages in clinical trials as an anti-Covid-19 drug.
The agency stated that there is great interest from the US government to pump an investment estimated at $ 500 million, after President Donald Trump attributed the credit to a similar treatment that contributed to the recovery from Corona.
Vaccine plan
In a statement, Astra said two trials of more than 6,000 people would begin in the next few weeks, with further plans for another 4,000 adults to test the antibody drug as a treatment. The drug will be evaluated for its ability to avoid infection for up to a year in some people and as a preventative medicine once patients are exposed to the virus in others. And Astra is one of a number of companies exploring monoclonal antibodies as a way to prevent and treat Covid-19, which could be key to populations at high risk who may not respond well to the vaccine. The United States has already obtained hundreds of thousands of doses of experimental treatments.
Permits
Eli Lilly and Regenero last week asked the US Food and Drug Administration for emergency use permits, but they haven’t been obtained yet. Trump said Regeneron’s combination of antibodies was a key factor in his apparent recovery from the coronavirus. at the same time.